CSF synaptic proteins are associated with risk of MCI symptom onset and long‐term brain atrophy

TL;DR

Higher levels of synaptic proteins VGF and DPP6 in cerebrospinal fluid may delay the onset of mild cognitive impairment and brain atrophy linked to Alzheimer's disease.

Contribution

Identifies VGF and DPP6 as potential resilience factors against Alzheimer's-related neurodegeneration, independent of traditional AD biomarkers.

Findings

Higher baseline levels of VGF and DPP6 were associated with lower risk of MCI symptom onset.

Higher VGF and DPP6 levels correlated with less atrophy in Alzheimer's signature brain regions over time.

These associations were only observed after accounting for traditional AD biomarker levels.

Abstract

More abnormal cerebrospinal fluid (CSF) levels of amyloid and tau among cognitively unimpaired individuals are associated with higher risk of mild cognitive impairment (MCI) or dementia due to Alzheimer's disease (AD). However, the predictive accuracy of these markers alone is limited. This study examined whether novel synaptic markers and neural signaling proteins are associated with time to onset of MCI symptoms and with long‐term neurodegeneration, based on MRI, after accounting for traditional CSF AD biomarker levels.

CSF was collected from 268 cognitively unimpaired BIOCARD Study participants (mean baseline age = 57.7 years; mean follow‐up = 16.3 years; n = 77 progressed to MCI/dementia; see Table 1). Levels of eight peptides involved in neuronal signaling were measured, using quantitative parallel reaction monitoring mass spectrometry: CNTFR, GFRA3, VGF, ACHE, NCAM1, DPP6, GPC1, and CARTPT. Levels of Aβ42/Aβ40 and p‐tau181 were measured from the same CSF specimens using Lumipulse assays. Atrophy on volumetric MRI scans was quantified from 213 participants as two composites: (1) AD signature regions (SPARE‐AD) and (2) regions indexing brain aging (SPARE‐BA). All analyses covaried age, sex, years of education, and APOE‐e4 status.

In Cox regression models, after accounting for covariates and baseline AD biomarker levels, higher baseline levels of both neurosecretory protein VGF and dipeptidyl peptidase‐like protein 6 (DPP6) were associated with a lower risk of MCI symptom onset (both p <0.04, see Table 2. In mixed effect models, higher levels of VGF and DPP6 were also associated with less atrophy over time in AD‐signature regions (see Table 3), and higher VGF was associated with less age‐related atrophy. Interestingly, when AD biomarker levels were not accounted for, none of the signaling proteins were associated with MCI symptom onset or MRI atrophy.

These findings suggest that among cognitively unimpaired individuals, higher levels of the synaptic proteins VGF and DPP6 may slow the onset of the symptomatic phase of AD as well as longitudinal atrophy in AD‐vulnerable regions, independently of AD pathology levels. These findings support the view that VGF and DPP6 may be resilience factors against neurodegeneration and cognitive decline and represent fruitful targets for novel therapeutics.

Figures